Cambrige’s Cyted Health Raises Over €37 Million In Series B Round

The funding round was led by EQT Life Sciences through its EQT Health Economics strategy, with Advent Life Sciences and British Business Bank as co-leaders. Existing investors Morningside and BGF also continued to support the company.

"This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting oesophageal diseases earlier", said Marcel Gehrung, CEO and Co-founder of Cyted Health. "This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio."

Founded in 2020, Cyted Health is a gastrointestinal molecular diagnostics company dedicated to enhancing the early detection and prevention of oesophageal adenocarcinoma through innovative, minimally invasive tests.

With over 35,000 tests performed and a strong portfolio of peer-reviewed research, its platform is widely used across the UK’s National Health Service. Originating from experts at the University of Cambridge, Cyted combines minimally invasive cell collection with proprietary biomarker discovery to revolutionise the detection of pre-cancerous, cancerous, and inflammatory oesophageal conditions.

Science Minister Lord Vallance said: "I am pleased to see the British Business Bank back Cyted a company whose growth demonstrates the ability of our universities to turn world-class life sciences research into successful commercial opportunities with the potential to improve people’s lives. Life sciences form a critical part of this Government’s ambitions for both the economy and healthcare – and through our Life Sciences Sector Plan, we will continue to support the industry to even greater success."

Cyted’s Series B funding comes after the recent launch of its DETECT-ME clinical validation study, which began enrolling patients at multiple US sites in March 2025.

This study aims to validate the clinical performance of Cyted’s latest assays and molecular tests for detecting oesophageal conditions using EndoSign, an FDA 510(k)-cleared device for minimally invasive oesophageal cell collection, combined with advanced biomarker testing.

Bruno Holthof, Partner at EQT Life Sciences, commented: "Cyted is strongly positioned to redefine the standard of care in upper GI diagnostics worldwide. Its minimally invasive diagnostics platform is the standout innovation to capture this significant market opportunity, and we’re delighted to add the company to our portfolio."

The funding will help Cyted grow faster in the US build on its strong presence in the UK and develop more advanced diagnostic tests. Oesophagal cancer is one of the deadliest cancers globally, with only a 20% survival rate, making early detection crucial.

Carmine Circelli, Director, Life Sciences at British Business Bank, added: "Cyted is an excellent example of the kind of high-impact business we aim to back. Their innovation has the potential to transform early cancer detection and create lasting health outcomes both in the UK and globally."

About Cyted Health

Founded in 2020 Cyted Health is changing digestive healthcare by creating simple non-invasive tests that don’t require traditional endoscopy. Their innovative approach enables early disease detection and improves access to care making digestive health solutions available to everyone, everywhere.